List of Stem Cells Companies in Pennsylvania - 6

Accelerated Biosciences Corp. is commercializing human trophoblast stem cells isolated from the trophectoderm of embryos from women with ectopic pregnancies. hTSCs are ethically sourced and have immune-privileged characteristics. It is an abundant and dynamic pluripotent stem cell platform for basic research, disease modeling, toxicology, drug discovery, and cell therapy.

BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. Century Therapeutics, Inc. has a research collaboration with Outpace Bio, Inc. for CAR engineering. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

IO Biosciences develops allogeneic, gene modified cell therapies that treat cancers. Leveraging a proprietary lifesaving gene editing system and cell source, we create a unique opportunity to develop and manufacture of-the-shelf gene modified cell therapies. Taking vision from concept to reality - literally starting as a virtual, home-based biotech start-up last year, IO Biosciences has evolved to a team of 5 with office space and lab facility. Our state of the art CRISPOR gene editing methods create a new generation of universal “plug and play” cell sources for research and gene modified cell therapies treating cancers. This innovative system allows current personalized therapies to be transformed into manufactured off-the-shelf treatments and will greatly improve patient access at a competitive price point.

Organoid Therapeutics is developing organoid-based technologies to correct hormone deficiencies in patients and streamline drug discovery and toxicology testing in the lab.

Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.